Cottini Francesca, Hideshima Teru, Suzuki Rikio, Tai Yu-Tzu, Bianchini Giampaolo, Richardson Paul G, Anderson Kenneth C, Tonon Giovanni
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Cancer Discov. 2015 Sep;5(9):972-87. doi: 10.1158/2159-8290.CD-14-0943. Epub 2015 Jun 16.
Ongoing DNA damage is a common feature of epithelial cancers. Here, we show that tumor cells derived from multiple myeloma, a disease of clonal plasma cells, demonstrate DNA-replicative stress, leading to DNA damage. We identified a poor-prognosis subset of multiple myeloma with extensive chromosomal instability and replicative stress, which rely on ATR to compensate for DNA-replicative stress; conversely, silencing of ATR or treatment with a specific ATR inhibitor triggers multiple myeloma cell apoptosis. We show that oncogenes, such as MYC, induce DNA damage in multiple myeloma cells not only by increased replicative stress, but also via increased oxidative stress, and that reactive oxygen species-inducer piperlongumine triggers further DNA damage and apoptosis. Importantly, ATR inhibition combined with piperlongumine triggers synergistic multiple myeloma cytotoxicity. This synthetic lethal approach, enhancing oxidative stress while concomitantly blocking replicative stress response, provides a novel combination targeted therapy to address an unmet medical need in this subset of multiple myeloma.
Multiple myeloma remains an incurable disease. We have identified a subset of multiple myeloma patients with poor prognosis, whose tumors present chromosomal instability, replicative and oxidative stress, and DNA damage. We define a synthetic lethal approach enhancing oxidative stress while targeting replicative stress response, inducing tumor cell apoptosis in this patient subset. Cancer Discov; 5(9); 972-87. ©2015 AACR.This article is highlighted in the In This Issue feature, p. 893.
持续性DNA损伤是上皮癌的一个常见特征。在此,我们表明,源自多发性骨髓瘤(一种克隆性浆细胞疾病)的肿瘤细胞表现出DNA复制应激,导致DNA损伤。我们鉴定出一个预后不良的多发性骨髓瘤亚组,其具有广泛的染色体不稳定性和复制应激,这些细胞依赖ATR来补偿DNA复制应激;相反,沉默ATR或用特定的ATR抑制剂处理会触发多发性骨髓瘤细胞凋亡。我们表明,癌基因,如MYC,不仅通过增加复制应激,还通过增加氧化应激在多发性骨髓瘤细胞中诱导DNA损伤,并且活性氧诱导剂胡椒碱会触发进一步的DNA损伤和凋亡。重要的是,ATR抑制与胡椒碱联合触发协同的多发性骨髓瘤细胞毒性。这种合成致死方法,在增强氧化应激的同时阻断复制应激反应,为解决这一多发性骨髓瘤亚组中未满足的医疗需求提供了一种新的联合靶向治疗。
多发性骨髓瘤仍然是一种无法治愈的疾病。我们已经鉴定出一个预后不良的多发性骨髓瘤患者亚组,其肿瘤表现出染色体不稳定性、复制和氧化应激以及DNA损伤。我们定义了一种合成致死方法,在增强氧化应激的同时靶向复制应激反应,在该患者亚组中诱导肿瘤细胞凋亡。《癌症发现》;5(9);972 - 87。©2015美国癌症研究协会。本文在本期特刊第893页重点介绍。